emalexadmin According to reporting by Iqbal Pittalwala at the University of California, Riverside, a team led by a UC-Riverside psychiatrist “has tested the orally administered investigational medication ecopipam on adults who stutter in an open-label, uncontrolled clinical trial and found that it reduced their stuttering symptoms … Read more
(CHICAGO, August 28, 2019) – Emalex Biosciences, Inc. (Emalex), a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, announced today that it has received Fast Track designation for its investigational product, ecopipam, from the U.S. Food and Drug Administration (FDA) for … Read more
CHICAGO (August 14, 2019) – Emalex Biosciences, Inc., a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, announced today that the first patient was recently enrolled in the company’s international Phase 2b study to evaluate the efficacy and safety of ecopipam … Read more
CHICAGO, IL, August 6, 2019 — Emalex Biosciences Inc., a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, today announced the appointment of Atul Mahableshwarkar, MD, as Senior Vice President of Drug Development. In this capacity, Dr. Mahableshwarkar will provide leadership … Read more
CHICAGO – August 14, 2018 – Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug … Read more